AACR and Bayer Offering Research Grants

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Association for Cancer Research and Bayer announced the 2016 AACR-Bayer Innovation and Discovery Grants program for meritorious projects that examine novel targets and biomarkers in oncology research.

The grants will promote the Bayer Grants4Targets initiative, originally introduced in 2009, to provide new treatment options for cancers with high unmet medical need, encourage innovation and translation of ideas from basic research into novel drugs, and foster collaborations between academic groups and the pharmaceutical industry.

The research proposed for funding should examine novel therapeutic targets focusing on the following oncology research areas: inhibition of cell proliferation; survival signaling; transcription and chromatin modulation; cell cycle regulation; tumor metabolism; hypoxia; immunotherapy; and antibody-drug conjugates.

Each grant will provide $10,000 to $25,000 over a period of one year, with the grant term to begin July 1. All the recipients will be offered the opportunity to work with a Bayer mentor who will provide guidance, expertise, and/or tools to accelerate the translation of their scientific idea.

To complete an application, please visit http://myaacr.aacr.org. Applications must be submitted by Jan. 18. Additional inquiries may be directed to Shaun Fitzpatrick at grants@aacr.org.

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login